Evidence map›Paper›PMID 18299413›Full record

ArticleAntimicrobial agents and chemotherapy2008

Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.

Theodouli Stergiopoulou, Joseph Meletiadis, Tin Sein, Paraskevi Papaioannidou, Ioannis Tsiouris, Emmanuel Roilides, Thomas J Walsh

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Metrics of Antifungal Effects of Ciprofloxacin onJournal of fungi (Basel, Switzerland) · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Theodouli StergiopoulouImmunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Joseph Meletiadis
Tin Sein
Paraskevi Papaioannidou
Ioannis Tsiouris
Emmanuel Roilides
Thomas J Walsh
National Cancer Institute · USAristotle University of Thessaloniki · GRHippocration General Hospital · GR

Funding

Treatment of Infections in Immunocompromised Children with Cancer, HematopoieticZ01SC006830 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI WALSH, THOMAS J. · 1996 to 2008
$5.8M
Treatment of Infections in Immunocompromised ChildrenZIASC006830 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WALSH, THOMAS J. · 2009 to 2009
$2.4M
Intramural NIH HHS
6 · The paper itself

Abstract

Patients suffering from invasive mycoses often receive concomitant antifungal therapy and antibacterial agents. Assessment of pharmacodynamic interactions between antifungal and antibacterial agents is complicated by the absence of a common antifungal end point for both agents. Ciprofloxacin has no intrinsic antifungal activity but may interact with antifungal agents, since it inhibits DNA gyrase (topoisomerase II), which is abundant in fungi. We therefore employed isobolographic analysis adapted to incorporate a nonactive agent in order to analyze the potential in vitro interaction between the fluoroquinolone ciprofloxacin and several representative antifungal agents against Candida albicans and Aspergillus fumigatus strains by using a microdilution checkerboard technique. In agreement with earlier in vitro studies, conventional fractional inhibitory concentration index analysis was unable to detect interactions between ciprofloxacin and antifungal agents. However, isobolographic analysis revealed significant pharmacodynamic interactions between antifungal agents and ciprofloxacin against C. albicans and A. fumigatus strains. Amphotericin B demonstrated concentration-dependent interactions for both species, with synergy (interaction indices, 0.14 to 0.81) observed at ciprofloxacin concentrations of <10.64 microg/ml. Synergy (interaction indices, 0.10 to 0.86) was also found for voriconazole and caspofungin against A. fumigatus. Isobolographic analysis may help to elucidate the pharmacodynamic interactions between antifungal and non-antifungal agents and to develop better management strategies against invasive candidiasis and aspergillosis.

Indexed as

Anti-Bacterial AgentsAntifungal AgentsAspergillus fumigatusCandida albicansCiprofloxacinDose-Response Relationship, DrugDrug AntagonismDrug InteractionsDrug SynergismHumansMicrobial Sensitivity TestsRegression AnalysisAnti-Bacterial AgentsAntifungal AgentsCiprofloxacin

Identifiers

PMID18299413
PMCPMC2415767
OpenAlexW2145597811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.